HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering
Listing milestone positions HanchorBio to strengthen institutional visibility, advance its FBDB™ platform, and expand a growing pipeline spanning oncology and broader immune-mediated diseases TAIPEI, SHANGHAI and SAN FRANCISCO, March 25, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation multifunctional biologics across oncology and immune-related diseases, today announced that it has received approval...
VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial
Pivotal Phase II/III clinical trial underway, aiming for US and European market approval in 2028 A 'truly transformative' regenerative medicine targeting a multi-million patient population with no existing curative treatment Fully biological transplant eliminates need for immunosuppression and restores natural function Scalable process protected by 92 granted patents CVI market projected...
BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States
BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosing SUZHOU, China, March 25, 2026 /PRNewswire/ -- BrightGene Bio-Medical Technology Co., Ltd. (SSE: 688166, "BrightGene" or "the Company") today announced positive topline results from Phase 1 clinical studies of BGM0504, an investigational oral GLP-1/GIP dual receptor agonist, in adult participants in...
Fujitsu and The University of Osaka develop new technologies for chemical material energy calculations on early-FTQC quantum computers
Contributing to the early application of quantum computers in drug discovery and new material development TOKYO, March 25, 2026 /PRNewswire/ -- Fujitsu Limited and the Center for Quantum Information and Quantum Biology at The University of Osaka today announced the development of a new technology designed to accelerate the industrial application of quantum...
Open-Sourcing to Empower, AI to Lead Medicine: “SurgMotion”, the Best-in-class Surgical Video Foundation Model, Officially Launched
HONG KONG, March 25, 2026 /PRNewswire/ -- On 24 March, the Centre for Artificial Intelligence and Robotics (CAIR), Hong Kong Institute of Science & Innovation (HKISI), and the Chinese Academy of Sciences unveiled "SurgMotion" — a surgical video foundation model — at the Hong Kong Science and Technology Parks Shenzhen Branch. The launch marks a significant leap in surgical...
Asia Pacific Consumers Lack Confidence to Achieve Economic Goals – Herbalife Survey
HONG KONG, March 25, 2026 /PRNewswire/ -- Herbalife, a premier health and wellness company and community and platform, released new findings from its Asia Pacific (APAC) Health and Economic Empowerment Survey 2025, where only two in five (43%) consumers feel very empowered to improve their economic wellbeing, and only one in three are...
Akeso Advances “IO 2.0 + ADC 2.0” Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
HONG KONG, March 25, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1, a first-in-class Trop2 /Nectin4 bispecific antibody-drug conjugate (ADC), and AK138D1, an innovative HER3-targeting ADC. The studies...
From SCAN to SPARK: Galaxy Brain Scientific Enables a New Paradigm in Non-invasive, Personalized Precision Treatment for Parkinson’s Disease
BEIJING, March 25, 2026 /PRNewswire/ -- A research team led by Prof. Hesheng Liu, founder and Chief Scientific Officer of Galaxy Brain Scientific Inc., has published a study in Nature Neuroscience demonstrating that Deep Brain Stimulation (DBS) achieves therapeutic efficacy in Parkinson's disease (PD) by remodeling the SPARK circuit. (https://www.nature.com/articles/s41593-026-02228-w) The findings build directly on the team's previous identification of a...
Hope Medicine Announces First Patient Dosed in the Phase III Clinical Trial for Endometriosis
SHANGHAI, March 25, 2026 /PRNewswire/ -- Hope Medicine Inc., a science-driven, clinical-stage innovative biopharmaceutical company, announced that the first patient has been dosed in the Phase III clinical trial of HMI-115, its first-in-class monoclonal antibody with global rights, for the treatment of endometriosis. The dosing took place at the leading study site in China, Peking Union Medical College...
Fosun Pharma Announces 2025 Annual Results
Innovation and Globalization Propel Fosun Pharma's High-Quality Growth SHANGHAI, March 24, 2026 /PRNewswire/ -- On 24 March, 2026, Fosun Pharma ("the company", stock code: 600196.SH; 02196.HK), an innovation-driven global pharmaceutical and healthcare group, announced its 2025 annual operating results (the reporting period). Powered by the dual engines of innovation and globalization, Fosun Pharma achieved total operating revenue of RMB 41.662...
